BridgeBio Pharma, Inc. Payments to Acquire Marketable Securities
BridgeBio Pharma, Inc. (BBIO) reported Payments to Acquire Marketable Securities of $7.91 million for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2025-08-05
- BridgeBio Pharma, Inc. payments to acquire marketable securities for the quarter ending 2025-06-30 was $7.91M, a 84.00% decline year-over-year.
- BridgeBio Pharma, Inc. payments to acquire marketable securities for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- BridgeBio Pharma, Inc. payments to acquire marketable securities for the quarter ending 2024-12-31 was $0.00.
- BridgeBio Pharma, Inc. payments to acquire marketable securities for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- BridgeBio Pharma, Inc. payments to acquire marketable securities for fiscal 2024 was $93.81M, a 215.59% increase from fiscal 2023.
- BridgeBio Pharma, Inc. payments to acquire marketable securities for fiscal 2023 was $29.73M, a 78.38% decline from fiscal 2022.
- BridgeBio Pharma, Inc. payments to acquire marketable securities for fiscal 2022 was $137.49M, a 76.69% decline from fiscal 2021.
- BridgeBio Pharma, Inc. payments to acquire marketable securities for fiscal 2021 was $589.89M, a 104.93% increase from fiscal 2020.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2025-06-30 | $7.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $7.91M 10-Q · filed 2025-08-05 | $7.91M derived: sum of 3 quarters · filed 2025-08-05 | $7.91M derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2025-04-29 | $0.00 derived: sum of 2 quarters · filed 2025-04-29 | $0.00 derived: sum of 3 quarters · filed 2025-04-29 | $49.42M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $0.00 derived: sum of 2 quarters · filed 2025-02-20 | $49.42M derived: sum of 3 quarters · filed 2025-08-05 | $93.81M 10-K · filed 2025-02-20 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $49.42M derived: sum of 2 quarters · filed 2025-08-05 | $93.81M 10-Q · filed 2024-11-12 | $93.81M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-06-30 | $49.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $93.81M 10-Q · filed 2025-08-05 | $93.81M derived: sum of 3 quarters · filed 2025-08-05 | $103.78M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $44.40M 10-Q · filed 2025-04-29 | $44.40M derived: sum of 2 quarters · filed 2025-04-29 | $54.37M derived: sum of 3 quarters · filed 2025-04-29 | $74.12M derived: sum of 4 quarters · filed 2025-04-29 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $9.97M derived: sum of 2 quarters · filed 2025-02-20 | $29.73M derived: sum of 3 quarters · filed 2025-02-20 | $29.73M 10-K · filed 2025-02-20 |
| 2023-09-30 | $9.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $29.73M derived: sum of 2 quarters · filed 2024-11-12 | $29.73M 10-Q · filed 2024-11-12 | $32.58M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $19.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $19.75M 10-Q · filed 2024-08-01 | $22.61M derived: sum of 3 quarters · filed 2025-02-20 | $37.64M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-02 | $2.86M derived: sum of 2 quarters · filed 2025-02-20 | $17.88M derived: sum of 3 quarters · filed 2025-02-20 | $81.77M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $2.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $17.88M derived: sum of 2 quarters · filed 2025-02-20 | $81.77M derived: sum of 3 quarters · filed 2025-02-20 | $137.49M 10-K · filed 2025-02-20 |
| 2022-09-30 | $15.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $78.91M derived: sum of 2 quarters · filed 2023-11-02 | $134.63M 10-Q · filed 2023-11-02 | $149.05M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $63.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $119.61M 10-Q · filed 2023-08-03 | $134.03M derived: sum of 3 quarters · filed 2024-02-22 | $199.57M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $55.72M 10-Q · filed 2023-05-04 | $70.14M derived: sum of 2 quarters · filed 2024-02-22 | $135.68M derived: sum of 3 quarters · filed 2024-02-22 | $266.32M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $14.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $79.96M derived: sum of 2 quarters · filed 2024-02-22 | $210.60M derived: sum of 3 quarters · filed 2024-02-22 | $589.89M 10-K · filed 2024-02-22 |
| 2021-09-30 | $65.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $196.19M derived: sum of 2 quarters · filed 2022-11-03 | $575.48M 10-Q · filed 2022-11-03 | $593.53M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $130.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $509.93M 10-Q · filed 2022-08-04 | $527.98M derived: sum of 3 quarters · filed 2023-02-23 | $628.99M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $379.29M 10-Q · filed 2022-05-05 | $397.34M derived: sum of 2 quarters · filed 2023-02-23 | $498.34M derived: sum of 3 quarters · filed 2023-02-23 | |
| 2020-12-31 | $18.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $119.05M derived: sum of 2 quarters · filed 2023-02-23 | $287.85M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $101.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $269.80M 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $168.80M 10-Q · filed 2021-08-05 | |||
| 2019-12-31 | $15.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $212.90M 10-K · filed 2022-02-25 | ||
| 2019-09-30 | $197.75M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |